Literature DB >> 12920249

Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis).

Daphne Vasconcelos1, Roy Barnewall, Michael Babin, Robert Hunt, James Estep, Carl Nielsen, Robert Carnes, John Carney.   

Abstract

Anthrax is considered a serious biowarfare and bioterrorism threat because of its high lethality, especially by the inhalation route. Rhesus macaques (Macaca mulatta) are the most commonly used nonhuman primate model of human inhalation anthrax exposure. The nonavailability of rhesus macaques necessitated development of an alternate model for vaccine testing and immunologic studies. This report describes the median lethal dose (LD(50)) and pathology of inhalation anthrax in cynomolgus macaques (Macaca fascicularis). Gross and microscopic tissue changes were reviewed in 14 cynomolgus monkeys that died or were killed after aerosol exposure of spores of Bacillus anthracis (Ames strain). The LD(50) and 95% confidence intervals were 61800 (34000 to 110000) colony-forming units. The most common gross lesions were mild splenomegaly, lymph node enlargement, and hemorrhages in various organs, particularly involving the meninges and the lungs. Mediastinitis, manifested as hemorrhage or edema, affected 29% of the monkeys. Microscopically, lymphocytolysis occurred in the intrathoracic lymph nodes and spleens of all animals, and was particularly severe in the spleen and in germinal centers of lymph nodes. Hemorrhages were common in lungs, bronchial lymph nodes, meninges, gastrointestinal tract, and mediastinum. These results demonstrate that the Ames strain of B. anthracis is lethal by the inhalation route in the cynomolgus macaque. The LD(50) of the Ames strain of B. anthracis was within the expected experimental range of previously reported values in the rhesus monkey in an aerosol challenge. The gross and microscopic pathology of inhalation anthrax in the cynomolgus monkey is remarkably similar to that reported in rhesus monkeys and humans. The results of this study are important for the establishment of an alternative nonhuman primate model for evaluation of medical countermeasures against inhalational anthrax.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920249     DOI: 10.1097/01.lab.0000080599.43791.01

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  61 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

Review 2.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

3.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

4.  A dynamic dose-response model to account for exposure patterns in risk assessment: a case study in inhalation anthrax.

Authors:  Bryan T Mayer; James S Koopman; Edward L Ionides; Josep M Pujol; Joseph N S Eisenberg
Journal:  J R Soc Interface       Date:  2010-11-10       Impact factor: 4.118

5.  Pathophysiological manifestations in mice exposed to anthrax lethal toxin.

Authors:  Nathan C Culley; David M Pinson; Anuradha Chakrabarty; Matthew S Mayo; Steven M LeVine
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Histopathology in a murine model of anthrax.

Authors:  Scott Duong; Lucius Chiaraviglio; James E Kirby
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

Review 7.  Persistence of category A select agents in the environment.

Authors:  Ryan Sinclair; Stephanie A Boone; David Greenberg; Paul Keim; Charles P Gerba
Journal:  Appl Environ Microbiol       Date:  2007-12-07       Impact factor: 4.792

8.  Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.

Authors:  Thi-Sau Migone; Sally Bolmer; John Zhong; Al Corey; Daphne Vasconcelos; Matthew Buccellato; Gabriel Meister
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

9.  Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax.

Authors:  Cynthia A Rossi; Melanie Ulrich; Sarah Norris; Douglas S Reed; Louise M Pitt; Elizabeth K Leffel
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

10.  Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.

Authors:  Tolga Sursal; Deborah J Stearns-Kurosawa; Kiyoshi Itagaki; Sun-Young Oh; Shiqin Sun; Shinichiro Kurosawa; Carl J Hauser
Journal:  Shock       Date:  2013-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.